Status at 3 months in patients with symptoms at baseline
| Total (n=2052) | Germany (n=795) | France (n=542) | UK (n=715) | P value | |
| Patients available/lost to FU, n (%) | 2039/13 | 786/9 | 542/0 | 711/4 | |
| Symptomatic patients, n (%) | 1623 (79.6) | 705 (89.7) | 390 (72.0) | 528 (74.3) | <0.001 |
| AVR planned, n (%) | 1289 (79.4) | 627 (88.9) | 332 (85.1) | 330 (62.5) | <0.001 |
| AVR performed, n (%) | 1077 (83.6) | 574 (91.5) | 305 (91.9) | 198 (60.0) | <0.001 |
| TAVI, n (%) | 787 (73.1) | 482 (84.0) | 176 (57.7) | 129 (65.2) | <0.001 |
| SAVR, n (%) | 290 (26.9) | 92 (16.0) | 129 (42.3) | 69 (34.8) | |
| Time to AVR (days) | 26.2±25.1 | 25.1±24.9 | 19.0±20.2 | 40.3±27.1 | <0.001 |
| Time to TAVI (days) | 25.3±25.5 | 23.1±25.0 | 18.1±19.8 | 43.2±26.7 | <0.001 |
| Time to SAVR (days) | 28.6±23.9 | 35.6±21.9 | 20.3±20.8 | 34.9±27.2 | <0.001 |
| AVR not performed, n (%) | 212 (16.4) | 53 (8.5) | 27 (8.1) | 132 (40.0) | <0.001 |
| AVR not planned, n (%) | 334 (20.6) | 78 (11.1) | 58 (14.9) | 198 (37.5) | <0.001 |
AVR, aortic valve replacement; FU, follow-up; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.